Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States ...
Vaxil Bio has offloaded its CEO and is considering a fundamental shakeup of the business to free up enough cash to get a colorectal cancer drug into the clinic.
Vaxil’s Annual and Special Shareholders Meeting
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, March 07, 2022 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative...
NESS-ZIONA, Israel, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that at the Company's Annual and Special General Meeting, held virtually, on February 7, 2022, all resolutions were duly passed by shareholders.
NESS-ZIONA, Israel , Nov. 12, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative biotech company announces that the board of directors of the Corporation has appointed Zeifmans LLP as the Corporation’s new auditor, replacing MNP LLP. Vaxil has filed a Notice of Change of Auditor in respect of this change under its profile on SEDAR at www.sedar.com.